1-11 of 11
Milos D Miljkovic
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease

Milos D Miljkovic, Adam S. Asch, Gregory Orloff, Ralph Boccia, Jesús G Berdeja, Fevzi Altuntas, Stefan O. Ciurea, James F Howard, Jr., Tuan Vu, Bennett Myers, Nizar Chahin, Tahseen Mozaffar, Christopher M Jewell, Metin Kurtoglu
Journal: Blood
Blood (2024) 144 (Supplement 1): 2080.
https://doi.org/10.1182/blood-2024-203585
Published: 2024
Journal Articles

Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma

Max J Gordon, Milos D Miljkovic, Samuel Ng, Rahul Lakhotia, Christopher Melani, Kevin Conlon, James D. Phelan, Bonita Bryant, Laura M Yee, Stefania Pittaluga, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2024) 144 (Supplement 1): 984.
https://doi.org/10.1182/blood-2024-199196
Published: 2024
Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, Milos D. Miljkovic, James D. Phelan, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Anna Marie Juanitez, Amynah Pradhan, Amy Hillsman, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2021) 138 (Supplement 1): 3537.
https://doi.org/10.1182/blood-2021-147032
Published: 2021
Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Craig J. Thomas, PhD, Michele Ceribelli, PhD, Frances Anne Tosto, MS, Craig A. Portell, MD, Rafic J. Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-141447
Published: 2020
Journal Articles

Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Rrelapsed/Refractory T-Cell Lymphoma

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Albert, RN, Deborah Allen, RN, Thomas A. Waldmann, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-142065
Published: 2020
Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3052.
https://doi.org/10.1182/blood-2019-130807
Published: 2019
Journal Articles

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, Jagan R. Muppidi, MD PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, Wyndham Wilson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2867.
https://doi.org/10.1182/blood-2019-125990
Published: 2019
Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1558.
https://doi.org/10.1182/blood-2019-128945
Published: 2019
Journal Articles

Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade

Daniel A. Rauch, Kevin C. Conlon, Murali Janakiram, Jonathan E. Brammer, John C. Harding, B. Hilda Ye, Xingxing Zang, Xiaoxin Ren, Sydney Olson, Xiaogang Cheng, Milos D. Miljkovic, Hemalatha Sundaramoorthi, Ancy Joseph, Zachary L. Skidmore, Obi Griffith, Malachi Griffith, Thomas A. Waldmann, Lee Ratner
Journal: Blood
Blood (2019) 134 (17): 1406–1414.
https://doi.org/10.1182/blood.2019002038
Published: 2019
Includes: Supplemental data
Journal Articles

Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia

Sigrid Dubois, PhD, Milos D. Miljkovic, MD, Thomas Fleisher, Jennifer Hsu, RN, Thomas A Waldmann, MD, Kevin C Conlon, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3840.
https://doi.org/10.1182/blood.V130.Suppl_1.3840.3840
Published: 2017
Journal Articles

End-of-Treatment CT and Serial FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma

Christopher Melani, MD, Ranjana H. Advani, MD, Mark Roschewski, MD, Kelsey M. Walters, BS, Clara C. Chen, MD, Lucia Barrato, MD, Mark A. Ahlman, MD, Milos D. Miljkovic, MD, Seth M. Steinberg, PhD, Margaret Shovlin, RN, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2859.
https://doi.org/10.1182/blood.V130.Suppl_1.2859.2859
Published: 2017